Amicogen Completes Proprietary ‘Transient Expression Media’ Technology…Securing a Next-Generation Expression Platform to Accelerate AI-Driven Drug Discovery - 금융경제플러스

[FNEplus = Mi-joo Lee] Biomaterials and healthcare company Amicogen announced that its independently developed transient expression media has demonstrated protein productivity improvements ranging from approximately 1.7 times up to a maximum of four times compared with conventional media, based on evaluations by domestic customers and internal verification. Transient expression media is a key research material used to rapidly express and validate drug candidate proteins, and its importance is growing rapidly in AI-driven drug discovery environments. While advances in AI have dramatically accelerated the speed of candidate molecule design, the experimental stages of protein expression and functional validation have continued to act as bottlenecks limiting overall research throughput. Recognizing this structural limitation, Amicogen developed its transient expression media using fully proprietary technology encompassing the entire process—from media design and manufacturing to securing quality reproducibility—going far beyond simple compositional adjustments. The recent validation results are being viewed as evidence that the technology can function as a core expression platform that directly determines research efficiency. In particular, the new transient expression media delivers not only high expression efficiency but also stable reproducibility that minimizes variability between production processes. This makes it highly optimized for AI-based research environments, where large numbers of candidate proteins must be repeatedly tested within short timeframes. The technology is expected to simultaneously enhance research speed and improve data reliability. Building on this technological achievement, Amicogen is currently engaging in discussions with global companies focused on AI-driven drug discovery and next-generation biomedical research. The company is also reviewing phased commercialization opportunities that extend beyond research-use media toward full-scale expression platform technologies. An Amicogen representative stated, “This transient expression media represents a highly meaningful expression platform technology capable of dramatically improving research efficiency,” adding, “We will continue to advance core infrastructure technologies that simultaneously meet the demands for speed and reproducibility required in the era of AI-driven drug development.”